@article{3061640,
    title = "Translocation t(12;13)(p13;q14) in a patient with imatinib-sensitive MDS/MPD associated with resistance to treatment: Review of the literature",
    author = "Diamantopoulos, P.T. and Athanasiadou, A. and Papakostas, E. and Gratsias, N. and Georgiou, G. and Mantzourani, M. and Andreopoulos, G. and Panagiotidis, P. and Aessopos, A. and Meletis, J. and Viniou, N.",
    journal = "Anti-Cancer Drug Design",
    year = "2011",
    volume = "22",
    number = "9",
    pages = "944-947",
    issn = "0266-9536, 1460-2148",
    doi = "10.1097/CAD.0b013e3283486ca4",
    keywords = "CD33 antigen;  CD34 antigen;  CD45 antigen;  cyclophosphamide;  cytarabine;  danazol;  etoposide;  Flt3 ligand;  hydroxyurea;  imatinib;  methylprednisolone;  microsomal aminopeptidase;  mitoxantrone;  platelet derived growth factor alpha receptor;  platelet derived growth factor beta receptor;  retinoblastoma protein;  transcription factor ETV6;  vincristine, acute granulocytic leukemia;  adult;  anemia;  blood analysis;  blood cell count;  bone marrow biopsy;  bone marrow examination;  cancer regression;  case report;  cytogenetics;  drug treatment failure;  drug withdrawal;  erythrocyte transfusion;  fatigue;  female;  fluorescence in situ hybridization;  gingiva bleeding;  granulocyte;  hematocrit;  hemolytic anemia;  human;  human cell;  human tissue;  karyotype;  karyotype 46,XX;  leukocyte;  leukopenia;  malaise;  mixed myelodysplastic myeloproliferative disease;  monotherapy;  physical examination;  polymerase chain reaction;  priority journal;  review;  thrombocytopenia;  treatment response;  upper gastrointestinal bleeding, Antineoplastic Agents;  Drug Resistance, Neoplasm;  Female;  Fusion Proteins, bcr-abl;  Humans;  Middle Aged;  Myelodysplastic Syndromes;  Myeloproliferative Disorders;  Piperazines;  Protein Kinase Inhibitors;  Pyrimidines;  Translocation, Genetic",
    abstract = "The category of myelodysplastic syndromes/myeloproliferative diseases (MDS/MPD) is a relatively new group of malignant hematologic diseases developed by the World Health Organization. These hematologic disorders lack the BCR/ABL fusion gene, although they can be associated with chromosomal translocations that involve genes encoding other protein kinases. Imatinib mesylate was recognized as a potent inhibitor of some of those kinases. We present a patient with a previously treated acute myeloid leukemia, who, after a 9-year-long remission, developed an MDS/MPD with normal karyotype, which initially responded to imatinib mesylate. Translocation t(12;13)(p12;q14) was detected after loss of response to imatinib treatment. Translocation t(12;13) is rare. It has been described in several hematologic malignancies including chronic myelomonocytic leukemia but not in MDS/MPD, previously described as Philadelphia-negative chronic myelogenous leukemia. Moreover, the correlation of this molecular abnormality with loss of efficacy of imatinib is unique in the literature. © 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins."
}